Position;Phosphorylation site;Methylation site;Ubiquitination site;Caspase cleavage site;S-Nitrosylation site;Acetylation site;Sumoylation site;Residue part of a linear motif;WT residue;Mutated residue;Sources;Cancer study;Cancer type;Genomic coordinates;Genomic mutation;Revel score
1;-;-;-;-;-;-;-;;M
2;-;-;-;-;-;-;-;;P
3;-;-;-;-;-;-;-;;S;W;COSMIC;-;carcinoma;hg38,chr16:87392435-87392435;hg38,chr16:87392435C>G;0.158
4;-;-;-;-;-;-;-;;E
5;-;-;-;-;-;-;-;;K
6;-;-;-;-;-;-;-;;T
7;-;-;-;-;-;-;-;;F
8;-;-;-;-;-;-;-;;K
9;-;-;-;-;-;-;-;;Q
10;-;-;-;-;-;-;-;14-3-3 binding phosphopeptide motif, 7, 10-14, ELM;R
11;-;-;-;-;-;-;-;14-3-3 binding phosphopeptide motif, 7, 10-14, ELM;R
12;-;-;-;-;-;-;-;14-3-3 binding phosphopeptide motif, 7, 10-14, ELM;T
13;-;-;-;-;-;-;-;14-3-3 binding phosphopeptide motif, 7, 10-14, ELM;F
14;-;-;-;-;-;-;-;14-3-3 binding phosphopeptide motif, 7, 10-14, ELM;E
15;-;-;-;-;-;-;-;;Q
16;-;-;-;-;-;-;-;;R;G;COSMIC;-;carcinoma;hg38,chr16:87398820-87398820;hg38,chr16:87398820A>G;0.762
17;-;-;-;-;-;-;-;;V
18;-;-;-;-;-;-;-;Endosome-Lysosome-Basolateral sorting signals, 15, 18-23, ELM;E
19;-;-;-;-;-;-;-;Endosome-Lysosome-Basolateral sorting signals, 15, 18-23, ELM;D;Y;cBioPortal;mixed_pipseq_2017;Mixed Cancer Types;hg19,chr16:87432435-87432435;hg19,chr16:87432435G>T;0.524
20;-;-;-;-;-;-;-;Endosome-Lysosome-Basolateral sorting signals, 15, 18-23, ELM;V
21;-;-;-;-;-;-;-;Endosome-Lysosome-Basolateral sorting signals, 15, 18-23, ELM;R;G;cBioPortal;skcm_tcga;Cutaneous Melanoma;hg19,chr16:87432441-87432441;hg19,chr16:87432441C>G;0.125
21;-;-;-;-;-;-;-;Endosome-Lysosome-Basolateral sorting signals, 15, 18-23, ELM;R;Q;cBioPortal,COSMIC;ucec_tcga, ucec_tcga_pan_can_atlas_2018, ucec_tcga_pub, ucs_jhu_2014;Endometrial Carcinoma, Uterine Carcinosarcoma/Uterine Malignant Mixed Mullerian Tumor, carcinoma;hg19,chr16:87432442-87432442, hg38,chr16:87398836-87398836;hg19,chr16:87432442G>A, hg38,chr16:87398836G>A;0.066
22;-;-;-;-;-;-;-;Endosome-Lysosome-Basolateral sorting signals, 15, 18-23, ELM;L
23;-;-;-;-;-;-;-;Endosome-Lysosome-Basolateral sorting signals, 15, 18-23, ELM;I
24;-;-;-;-;-;-;-;;R
25;-;-;-;-;-;-;-;;E
26;-;-;-;-;-;-;-;;Q
27;-;-;-;-;-;-;-;;H
28;-;-;-;-;-;-;-;;P;L;cBioPortal,COSMIC;skcm_tcga_pan_can_atlas_2018;Cutaneous Melanoma, malignant_melanoma;hg19,chr16:87432463-87432463, hg38,chr16:87398857-87398857;hg19,chr16:87432463C>T, hg38,chr16:87398857C>T;0.411
29;-;-;-;-;-;-;-;;T;A;cBioPortal,COSMIC;gbc_shanghai_2014;Gallbladder Cancer, carcinoma;hg19,chr16:87432465-87432465, hg38,chr16:87398859-87398859;hg19,chr16:87432465A>G, hg38,chr16:87398859A>G;0.147
30;-;-;-;-;-;-;-;;K
31;-;-;-;-;-;-;-;PP2A holoenzyme B56-docking site, 5, 31-36, ELM;I
32;-;-;-;-;-;-;-;PP2A holoenzyme B56-docking site, 5, 31-36, ELM;P;Q;cBioPortal;lusc_tcga_pub;Lung Squamous Cell Carcinoma;hg19,chr16:87432475-87432475;hg19,chr16:87432475C>A;0.755
33;-;-;-;-;-;-;-;PP2A holoenzyme B56-docking site, 5, 31-36, ELM;V
34;-;-;-;-;-;-;-;PP2A holoenzyme B56-docking site, 5, 31-36, ELM;I
35;-;-;-;-;-;-;-;PP2A holoenzyme B56-docking site, 5, 31-36, ELM;I;V;cBioPortal;mm_broad;mm;hg19,chr16:87435787-87435787;hg19,chr16:87435787A>G;0.284
36;-;-;-;-;-;-;-;PP2A holoenzyme B56-docking site, 5, 31-36, ELM;E
37;-;-;-;-;-;-;-;MAPK docking motifs, 3, 37-46, ELM;R;Q;cBioPortal;luad_tcga_pan_can_atlas_2018, nsclc_tcga_broad_2016, ucec_tcga_pan_can_atlas_2018;Endometrial Carcinoma, Lung Adenocarcinoma, Non-Small Cell Lung Cancer;hg19,chr16:87435794-87435794;hg19,chr16:87435794G>A;0.514
38;-;-;-;-;-;-;-;MAPK docking motifs, 3, 37-46, ELM;Y;H;cBioPortal,COSMIC;ucec_tcga, ucec_tcga_pan_can_atlas_2018, ucec_tcga_pub;Endometrial Carcinoma, carcinoma;hg19,chr16:87435796-87435796, hg38,chr16:87402190-87402190;hg19,chr16:87435796T>C, hg38,chr16:87402190T>C;0.363
39;-;-;-;-;-;-;-;MAPK docking motifs, 3, 37-46, ELM;K;R;cBioPortal;coad_tcga_pan_can_atlas_2018;Colon Adenocarcinoma;hg19,chr16:87435800-87435800;hg19,chr16:87435800A>G;0.065
40;-;-;-;-;-;-;-;MAPK docking motifs, 3, 37-46, ELM;G
41;-;-;-;-;-;-;-;MAPK docking motifs, 3, 37-46, ELM;E
42;-;-;-;-;-;-;-;MAPK docking motifs, 3, 37-46, ELM;K
43;-;-;-;-;-;-;-;MAPK docking motifs, 3, 37-46, ELM;Q
44;-;-;-;-;-;-;-;MAPK docking motifs, 3, 37-46, ELM;L
45;-;-;-;-;-;-;-;MAPK docking motifs, 3, 37-46, ELM;P
46;-;-;-;-;-;-;-;MAPK docking motifs, 3, 37-46, ELM;V
47;-;-;-;-;-;-;-;;L
48;-;-;-;-;-;-;-;Cyclin docking motif, 2, 48-56, ELM;D
49;-;-;-;-;-;-;-;Cyclin docking motif, 2, 48-56, ELM;K;N;cBioPortal;mixed_allen_2018;Mixed Cancer Types;hg19,chr16:87435831-87435831;hg19,chr16:87435831A>C;0.495
50;-;-;-;-;-;-;-;Cyclin docking motif, 2, 48-56, ELM;T
51;-;-;-;-;-;-;-;Cyclin docking motif, 2, 48-56, ELM;K
52;-;-;-;-;-;-;-;Cyclin docking motif, 2, 48-56, ELM;F
53;-;-;-;-;-;-;-;Cyclin docking motif, 2, 48-56, ELM;L
54;-;-;-;-;-;-;-;Cyclin docking motif, 2, 48-56, ELM;V
55;-;-;-;-;-;-;-;Cyclin docking motif, 2, 48-56, ELM;P
56;-;-;-;-;-;-;-;Cyclin docking motif, 2, 48-56, ELM;D;N;cBioPortal,COSMIC;prad_fhcrc, prad_p1000, stad_tcga, stad_tcga_pan_can_atlas_2018, stes_tcga_pub;Prostate Adenocarcinoma, Stomach Adenocarcinoma, carcinoma, stes;hg19,chr16:87435850-87435850, hg38,chr16:87402244-87402244;hg19,chr16:87435850G>A, hg38,chr16:87402244G>A;0.341
57;-;-;-;-;-;-;-;;H
58;-;-;-;-;-;-;-;;V
59;-;-;-;-;-;-;-;;N
60;-;-;-;-;-;-;-;;M;I;cBioPortal;blca_tcga_pan_can_atlas_2018, blca_tcga_pub_2017;Bladder Urothelial Carcinoma;hg19,chr16:87435864-87435864;hg19,chr16:87435864G>A;0.261
60;-;-;-;-;-;-;-;;M;V;COSMIC;-;carcinoma;hg38,chr16:87402256-87402256;hg38,chr16:87402256A>G;0.277
61;-;-;-;-;-;-;-;;S
62;-;-;-;-;-;-;-;NES Nuclear Export Signal, 17, 62-77, ELM;E
63;-;-;-;-;-;-;-;NES Nuclear Export Signal, 17, 62-77, ELM;L
64;-;-;-;-;-;-;-;NES Nuclear Export Signal, 17, 62-77, ELM;I
65;-;-;-;-;-;-;-;MAPK docking motifs, 4, 65-73, ELM|NES Nuclear Export Signal, 17, 62-77, ELM;K;E;cBioPortal,COSMIC;coadread_genentech;Colorectal Adenocarcinoma, carcinoma;hg19,chr16:87435877-87435877, hg38,chr16:87402271-87402271;hg19,chr16:87435877A>G, hg38,chr16:87402271A>G;0.314
66;-;-;-;-;-;-;-;MAPK docking motifs, 4, 65-73, ELM|NES Nuclear Export Signal, 17, 62-77, ELM;I
67;-;-;-;-;-;-;-;MAPK docking motifs, 4, 65-73, ELM|di Arginine retention/retrieving signal, 12, 67-70, ELM|NES Nuclear Export Signal, 17, 62-77, ELM;I
68;-;-;-;-;-;-;-;MAPK docking motifs, 4, 65-73, ELM|di Arginine retention/retrieving signal, 12, 67-70, ELM|di Arginine retention/retrieving signal, 13, 68-70, ELM|NES Nuclear Export Signal, 17, 62-77, ELM;R
69;-;-;-;-;-;-;-;MAPK docking motifs, 4, 65-73, ELM|di Arginine retention/retrieving signal, 12, 67-70, ELM|di Arginine retention/retrieving signal, 13, 68-70, ELM|di Arginine retention/retrieving signal, 14, 69-71, ELM|NES Nuclear Export Signal, 17, 62-77, ELM;R
70;-;-;-;-;-;-;-;MAPK docking motifs, 4, 65-73, ELM|di Arginine retention/retrieving signal, 12, 67-70, ELM|di Arginine retention/retrieving signal, 13, 68-70, ELM|di Arginine retention/retrieving signal, 14, 69-71, ELM|NES Nuclear Export Signal, 17, 62-77, ELM;R;C;cBioPortal;ucec_tcga_pan_can_atlas_2018;Endometrial Carcinoma;hg19,chr16:87436533-87436533;hg19,chr16:87436533C>T;0.467
70;-;-;-;-;-;-;-;MAPK docking motifs, 4, 65-73, ELM|di Arginine retention/retrieving signal, 12, 67-70, ELM|di Arginine retention/retrieving signal, 13, 68-70, ELM|di Arginine retention/retrieving signal, 14, 69-71, ELM|NES Nuclear Export Signal, 17, 62-77, ELM;R;H;COSMIC;-;carcinoma;hg38,chr16:87402928-87402928;hg38,chr16:87402928G>A;0.513
71;-;-;-;-;-;-;-;MAPK docking motifs, 4, 65-73, ELM|di Arginine retention/retrieving signal, 14, 69-71, ELM|NES Nuclear Export Signal, 17, 62-77, ELM;L
72;-;-;-;-;-;-;-;MAPK docking motifs, 4, 65-73, ELM|NES Nuclear Export Signal, 17, 62-77, ELM;Q
73;-;-;-;-;-;-;-;MAPK docking motifs, 4, 65-73, ELM|NES Nuclear Export Signal, 17, 62-77, ELM;L
74;-;-;-;-;-;-;-;NES Nuclear Export Signal, 17, 62-77, ELM;N
75;-;-;-;-;-;-;-;NES Nuclear Export Signal, 17, 62-77, ELM;A
76;-;-;-;-;-;-;-;NES Nuclear Export Signal, 17, 62-77, ELM;N
77;-;-;-;-;-;-;-;Endosome-Lysosome-Basolateral sorting signals, 16, 77-82, ELM|NES Nuclear Export Signal, 17, 62-77, ELM;Q
78;-;-;-;-;-;-;-;Endosome-Lysosome-Basolateral sorting signals, 16, 77-82, ELM;A
79;-;-;-;-;-;-;-;Endosome-Lysosome-Basolateral sorting signals, 16, 77-82, ELM;F
80;-;-;-;-;-;-;-;Endosome-Lysosome-Basolateral sorting signals, 16, 77-82, ELM;F
81;-;-;-;-;-;-;-;Endosome-Lysosome-Basolateral sorting signals, 16, 77-82, ELM;L
82;-;-;-;-;-;-;-;Endosome-Lysosome-Basolateral sorting signals, 16, 77-82, ELM;L;F;COSMIC;-;other;hg38,chr16:87402965-87402965;hg38,chr16:87402965G>T;0.295
83;-;-;-;-;-;-;-;;V
84;-;-;-;-;-;-;-;;N
85;-;-;-;-;-;-;-;;G
86;-;-;-;-;-;-;-;;H
87;-;-;-;-;-;-;-;;S
88;-;-;-;-;-;-;-;SH3 ligand, 10, 88-94, ELM;M
89;-;-;-;-;-;-;-;SH3 ligand, 10, 88-94, ELM;V;F;cBioPortal,COSMIC;lusc_tcga, lusc_tcga_pan_can_atlas_2018, lusc_tcga_pub, nsclc_tcga_broad_2016;Lung Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, carcinoma;hg19,chr16:87436590-87436590, hg38,chr16:87402984-87402984;hg19,chr16:87436590G>T, hg38,chr16:87402984G>T;0.578
90;-;-;-;-;-;-;-;WW domain ligands, 6, 90-95, ELM|SH3 ligand, 10, 88-94, ELM;S
91;-;-;-;-;-;-;-;SCF ubiquitin ligase binding Phosphodegrons, 0, 91-97, ELM|Cks1 ligand, 1, 91-96, ELM|WW domain ligands, 6, 90-95, ELM|SH3 ligand, 10, 88-94, ELM;V;I;COSMIC;-;carcinoma;hg38,chr16:87402990-87402990;hg38,chr16:87402990G>A;0.172
92;-;-;-;-;-;-;-;SCF ubiquitin ligase binding Phosphodegrons, 0, 91-97, ELM|Cks1 ligand, 1, 91-96, ELM|WW domain ligands, 6, 90-95, ELM|SH3 ligand, 10, 88-94, ELM;S
93;-;-;-;-;-;-;-;SCF ubiquitin ligase binding Phosphodegrons, 0, 91-97, ELM|Cks1 ligand, 1, 91-96, ELM|WW domain ligands, 6, 90-95, ELM|SH3 ligand, 10, 88-94, ELM;T
94;-;-;-;-;-;-;-;SCF ubiquitin ligase binding Phosphodegrons, 0, 91-97, ELM|Cks1 ligand, 1, 91-96, ELM|WW domain ligands, 6, 90-95, ELM|SH3 ligand, 10, 88-94, ELM;P
95;-;-;-;-;-;-;-;SCF ubiquitin ligase binding Phosphodegrons, 0, 91-97, ELM|Cks1 ligand, 1, 91-96, ELM|WW domain ligands, 6, 90-95, ELM;I
96;-;-;-;-;-;-;-;SCF ubiquitin ligase binding Phosphodegrons, 0, 91-97, ELM|Cks1 ligand, 1, 91-96, ELM;S
97;-;-;-;-;-;-;-;SCF ubiquitin ligase binding Phosphodegrons, 0, 91-97, ELM;E
98;-;-;-;-;-;-;-;;V;A;cBioPortal;lihc_amc_prv;lihc;hg19,chr16:87436618-87436618;hg19,chr16:87436618T>C;0.265
99;-;-;-;-;-;-;-;;Y
100;-;-;-;-;-;-;-;;E
101;-;-;-;-;-;-;-;;S
102;-;-;-;-;-;-;-;;E
103;-;-;-;-;-;-;-;;K
104;-;-;-;-;-;-;-;;D
105;-;-;-;-;-;-;-;;E
106;-;-;-;-;-;-;-;;D
107;-;-;-;-;-;-;-;;G
108;-;-;-;-;-;-;-;;F
109;-;-;-;-;-;-;-;;L
110;-;-;-;-;-;-;-;;Y
111;-;-;-;-;-;-;-;;M
112;-;-;-;-;-;-;-;;V
113;-;-;-;-;-;-;-;SH2 ligand, 9, 113-116, ELM;Y;C;cBioPortal,COSMIC;acbc_mskcc_2015, kich_tcga;Adenoid Cystic Breast Cancer, carcinoma, kich, malignant_melanoma;hg19,chr16:87436663-87436663, hg38,chr16:87403057-87403057;hg19,chr16:87436663A>G, hg38,chr16:87403057A>G;0.771
114;-;-;-;-;-;-;-;SH2 ligand, 9, 113-116, ELM|TRAF2 binding site, 11, 114-117, ELM;A
115;-;-;-;-;-;-;-;SH2 ligand, 9, 113-116, ELM|TRAF2 binding site, 11, 114-117, ELM;S
116;-;-;-;-;-;-;-;SH2 ligand, 9, 113-116, ELM|TRAF2 binding site, 11, 114-117, ELM;Q
117;-;-;-;-;-;-;-;TRAF2 binding site, 11, 114-117, ELM;E
118;-;-;-;-;-;-;-;;T
119;-;-;-;-;-;-;-;;F
120;-;-;-;-;-;-;-;PDZ ligands, 8, 120-125, ELM;G;R;cBioPortal,COSMIC;stad_utokyo;Stomach Adenocarcinoma, carcinoma;hg19,chr16:87436683-87436683, hg38,chr16:87403077-87403077;hg19,chr16:87436683G>A, hg38,chr16:87403077G>A;0.705
120;-;-;-;-;-;-;-;PDZ ligands, 8, 120-125, ELM;G;V;COSMIC;-;other;hg38,chr16:87403078-87403078;hg38,chr16:87403078G>T;0.678
121;-;-;-;-;-;-;-;PDZ ligands, 8, 120-125, ELM;M
122;-;-;-;-;-;-;-;PDZ ligands, 8, 120-125, ELM;K
123;-;-;-;-;-;-;-;PDZ ligands, 8, 120-125, ELM;L;S;cBioPortal,COSMIC;coadread_dfci_2016;Colorectal Adenocarcinoma, carcinoma;hg19,chr16:87436693-87436693, hg38,chr16:87403087-87403087;hg19,chr16:87436693T>C, hg38,chr16:87403087T>C;0.044
123;-;-;-;-;-;-;-;PDZ ligands, 8, 120-125, ELM;L;V;cBioPortal;ucec_tcga_pan_can_atlas_2018;Endometrial Carcinoma;hg19,chr16:87436692-87436692;hg19,chr16:87436692T>G;0.025
124;-;-;-;-;-;-;-;PDZ ligands, 8, 120-125, ELM;S
125;-;-;-;-;-;-;-;PDZ ligands, 8, 120-125, ELM;V
